| Presenter | Abstract title | Day |
|---|---|---|
| Christian Poulie | Discovery of β-arrestin-2 biased agonists of the 5-HT2A receptor based on 25cn-nboh | Thursday |
| Helena Aicher | Modulation of self-referential information processing, mindfulness, compassion, and other psychotherapy-relevant change mechanisms through ayahuasca-analogues – first insights from an intervention study with healthy humans | Thursday |
| Federico Cavanna | Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study | Thursday |
| Mauro Cavarra | Psychedelic-assisted psychotherapy – a systematic review of associated psychological interventions | Thursday |
| Olga Chernoloz | Randomized, double-blind, placebo-controlled study assessing the efficacy of microdosed psilocybin on reducing depression and/or anxiety levels in adults | Thursday |
| James Close | Co-design of a strategy for patient and public involvement in psychedelic research | Thursday |
| Laura de la Fuente | Temporal irreversibility of neural dynamics as a signature of consciousness | Thursday |
| Helle Kaasik | Chemistry of ayahuasca and pharmahuasca: interlaboratory comparison | Thursday |
| Maja Kohek | Ayahuasca and public health: health status of people who regularly participate in ayahuasca ceremonies in spain and the netherlands | Thursday |
| Eline Pottie | In vitro functional characterization of psychedelic substances using different 5-HT2AR bioassays | Thursday |
| Deborah Rudin | Classic psychedelics differentially activate serotonin 2a receptor signaling pathways | Thursday |
| Marcelo Falchi | LSD, madness and healing: mystical experiences as possible link between psychosis model and therapy model | Thursday |
| Federico Zamberlan | Understanding the molecular mechanisms of functional selectivity in psychedelics: deep learning applied to the conformational change and transcriptome fingerprint analysis | Thursday |
| James W. Sanders | Micro-phenomenology of the intravenous DMT experience | Thursday |
| Agnieszka Sekula | Virtual reality as a moderator of psychedelic-assisted psychotherapy | Thursday |
| Daniel Martins | Kosmicare: experimenting the future harm reduction interventions | Thursday |
| Eirini Argyri | Psychedelic-induced psychological transformations: calling for balance in the novel narratives | Friday |
| Julia Bornemann | Co-development of the study protocol for “psilocybin in patients with fibromyalgia: EEG-measured brain biomarkers of action” | Friday |
| James Curley | A thematic examination of the spiritual usage of cannabis | Friday |
| Hannah Douglass | Study protocol and 8-month progress update: psilocybin as a treatment for anorexia nervosa: a pilot study | Friday |
| Jerome Herpers | A five-step model to explain the functional mechanisms of MDMA-assisted therapy for post-traumatic stress disorder | Friday |
| Maggie Kiraga | Psychedelic microdosers report therapeutic motivations and longitudinal improvements in mood, mental health and psychomotor functioning relative to non-microdosing comparators | Friday |
| Vito Palmisano | Photoswitchable psychedelics | Friday |
| Joseph Peill | Validation of the psychological insight scale: a new scale to assess psychological insight following a psychedelic experience | Friday |
| Edriss Samani | Development of LIWC dictionaries for netnographic studies on psychedelics | Friday |
| Nige / Wai Fung Netzband / Tsang | Amazonian ayahuasca and mental health outcomes in an adapted traditional setting – an overview | Friday |
| Jan Thomann | Development of a bioanalytical method for quantifying mescaline and its metabolites in human plasma and urine. | Friday |
| Filip Tylš | Integration of ketamine-assisted psychotherapy into mental health: pilot results | Friday |
| Dóra Révész | A longitudinal and transcultural assessment of the relationship between psychedelic drug use, psychological well-being, post-traumatic growth, and covid-19 pandemic stress | Friday |
| Amir Lofti | Antidepressant properties of 5-MeO-DMT: a behavioral and pharmacological investigation | Friday |
| Villa / Jennifer Zaskia/ Montjoy | Serial intramuscular ketamine-assisted psychotherapy efficacy in chronic posttraumatic-stress disorder | Friday |
| Johannes Reckweg | A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-methoxy-n,n-dimethyltryptamine formulation (gh001) in healthy volunteers | Friday |
| Eline Haijen | Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: a prospective naturalistic study | Saturday |
| Tommaso Barba | Summer of love: effects of psychedelic drugs on sexual functioning in healthy and depressed subjects | Saturday |
| Jon Sharp | Analgesic potential of macro- and microdoses of classical psychedelics in chronic pain sufferers: a population survey | Saturday |
| Natalie Ertl | The effect of psilocybin therapy for depression on low-frequency brain activity in response to music | Saturday |
| Laura Kärtner | Psychedelic microdosing: more than “just” placebo? | Saturday |
| Pablo Mallaroni | The neurochemical substrates of psychedelic altered states of consciousness | Saturday |
| Lea Mertens | Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – rationale, study design and insights from individual cases | Saturday |
| Mikael Palner | Detailed neurobiological changes in the rat brain, mapped over one week following a single psychedelic dose of psilocybin | Saturday |
| Carolina Seybert | Psychotherapy approaches in psychedelic-assisted treatments: a systematic review | Saturday |
| Stefano Johannes Maria van der Aalst | Repeated intravenous esketamine treatment in patients with ECT-resistant major depression disorder | Saturday |
| Henry Whitfield | The spectrum of selves (SoS) model for psychedelic-assisted therapy: further developing the approach following a high-density longitudinal data study | Saturday |
| Isabel Wiessner | LSD, afterglow and hangover: increased episodic memory and verbal fluency, decreased cognitive flexibility | Saturday |
| Aleksandra Wingert | Examining the prevalence and impact of adverse life event re-experiencing during the ceremonial use of ayahuasca. | Saturday |
| Rayyan Zafar | Looking through the doors of perception: the past, present and future of psychedelics to treat addiction | Saturday |
| Ksenia Cassidy | Childhood trauma + ayahuasca = post-traumatic growth? | Saturday |
| David Reydellet | EEG connectivity during the DMT experience | Saturday |
| Benjamin Mudge | Including bipolar people in psychedelic research | Saturday |
Ready To Attend ICPR 2022?
Join the leading conference in Europe dedicated to advancing psychedelic research and therapies.
Want The Latest Updates?
Subscribe below to ICPR Newsletter and get all the latest updates, including discount tickets!
By clicking subscribe, I confirm to receive emails from the OPEN Foundation and agree with its privacy & terms.